Screener
Halozyme Therapeutics HALO Gain (loss) on disposal of assets
Gain (loss) on disposal of assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.
The source filing: Halozyme Therapeutics’s 10-Q, filed November 3, 2025.
- Filed
- Nov 3, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001159036-25-000045
| Line item | Nine Months Ended / September 30, 2025 | Nine Months Ended / September 30, 2024 |
|---|---|---|
| Amortization of debt discount | 5,556 | 5,506 |
| Accretion of premium on marketable securities, net | (3,200) | (8,520) |
| Realized loss (gain) on marketable securities | 73 | (7) |
| Loss on disposal of equipment | — | 1,678 |
| Lease payments recognized | 680 | 863 |
| Deferred income taxes | 17,402 | 15,824 |
| Changes in operating assets and liabilities | ||
| Accounts receivable, net and other contract assets | (37,580) | (51,533) |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's gain (loss) on disposal of assets?
- Halozyme Therapeutics (HALO) reported gain (loss) on disposal of assets of $0 in Q3 2025.
- What does gain (loss) on disposal of assets mean?
- Gains or losses recognized on the disposal of businesses, property, equipment, investments, or other assets at prices above or below their carrying value.
Ask your AI about Halozyme Therapeutics's gain (loss) on disposal of assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude